Premium
Agonistic beta2‐adrenergic autoantibodies in glaucoma
Author(s) -
Hohberger Bettina
Publication year - 2019
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2019.8137
Subject(s) - glaucoma , autoantibody , medicine , intraocular pressure , pathogenesis , blockade , agonistic behaviour , disease , ophthalmology , ocular hypertension , receptor , immunology , antibody , psychiatry , aggression
Abstract Glaucoma disease has a multifactorial pathogenesis with autoimmune components. Agonistic autoantibodies against β2‐adrenergic receptor autoantibodies (β2‐AAb) were observed in sera of patients with glaucoma and ocular hypertension, yet not in normal subjects. As data of a clinical proof‐of‐principle study showed that intraocular pressure (IOP) decreased after elimination of β2‐AAb by immunapharesis, a potential link to IOP was proposed. A specific blockade of these β2‐AAb could potential result in a novel medical strategy of glaucoma therapy.